In a recent amendment in Companies (Corporate Social Responsibility Policy) Rules, 2014, a new proviso has been added in Rule 2(1)(e), which provides that any company engaged in research and development activity of new vaccine, drugs, and medical devices in their normal course of business may undertake research and development activity of new vaccine, drugs, and medical devices related to COVID-19 for financial years 2020-21, 2021-22, and 2022-23, subject to the conditions that -
Moreover, Rule 6(1) has also been amended by removing the first proviso and allowing the companies to execute CSR activities in such activities, which are in the normal course of business of a company.
Your password has been successfully updated! Please login with your new password
The link is unavailable for your login. Please empanel with the ID Databank to access this feature. For more information, email firstname.lastname@example.org or call 1-800-102-3145.